GNFT (GNFT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GNFT (GNFT) trades at $8.95 with AI Score 69/100 (Grade B+). Genfit S. A. is a biopharmaceutical company focused on developing innovative treatments for metabolic and liver diseases. Market cap: $445.68M, Sector: Healthcare.
Price live · AI analysis from Jun 13, 2026Analyst Coverage for GNFT: GNFT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNFT against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
GNFT: 4/7 perspectives are bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →GNFT (GNFT) Healthcare & Pipeline Overview
Genfit S.A. is a biopharmaceutical innovator specializing in drug candidates and diagnostic solutions for metabolic and liver diseases, with a strong focus on clinical development and partnerships to enhance patient care.
What Is the Investment Thesis for GNFT?
Genfit S.A. is positioned for growth through its diverse pipeline of drug candidates and diagnostic solutions targeting significant unmet medical needs in the liver disease space. The company's lead product, Elafibranor, is in Phase 3 trials, which, if successful, could lead to substantial market entry and revenue generation. Additionally, the development of NIS4 technology for diagnosing NASH and fibrosis represents a strategic advantage, as the global NASH market is projected to grow significantly, driven by increasing prevalence rates. Genfit's partnerships with Labcorp and Genoscience Pharma further enhance its capabilities and market presence, providing additional revenue streams and collaborative opportunities. However, the company faces risks, including the challenges of clinical trial outcomes and market competition, which could impact its growth trajectory. Overall, Genfit's focus on innovative therapies and diagnostics positions it well within the expanding biotechnology sector.
Based on FMP financials and quantitative analysis
GNFT Key Highlights
- Market Cap of $445.68M reflects the company's current valuation in the biotechnology sector.
- Profit Margin of -127.4% indicates ongoing investment in R&D, typical for companies in clinical development stages.
- Gross Margin of 26.0% demonstrates the company's ability to manage costs associated with its product development.
- Beta of 0.87 suggests lower volatility compared to the broader market, which may appeal to risk-averse investors.
- No dividend yield as the company reinvests earnings into research and development to drive future growth.
Who Are GNFT's Competitors?
GNFT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| MRNA Moderna, Inc. | $81.41 | +2.06% | $32.30B | — |
| VRTX Vertex Pharmaceuticals Incorporated | $528.88 | +0.16% | $134.23B | 99 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| REGN Regeneron Pharmaceuticals, Inc. | $645.84 | -1.29% | $66.54B | 91 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNFT's Key Strengths?
- Innovative pipeline targeting significant unmet medical needs in liver diseases.
- Strong partnerships with established healthcare organizations.
- Experienced management team with a proven track record in biotechnology.
What Are GNFT's Weaknesses?
- High reliance on successful clinical trial outcomes for revenue generation.
- Negative profit margins reflecting ongoing investment in R&D.
- Limited market presence compared to larger pharmaceutical companies.
What Could Drive GNFT Stock Higher?
- Results from Phase 3 clinical trials for Elafibranor are anticipated, which could lead to market approval and revenue generation.
- Development of NIS4 technology for NASH diagnosis continues, with increasing demand for effective diagnostic tools.
- Potential partnership announcements for GNS561 could enhance development and commercialization efforts.
- Clinical trials for Nitazoxanide are progressing, with updates expected in the near future.
- Expansion of market presence through strategic collaborations and licensing agreements.
What Are the Key Risks for GNFT?
- Financial-distress signal — its Altman Z-Score of -0.05 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures could delay or prevent product commercialization, impacting revenue projections.
- Regulatory challenges may arise during the approval process for new drugs and diagnostics.
- Competition from larger pharmaceutical companies could hinder market penetration for Genfit's products.
- Market volatility may affect funding opportunities and investor sentiment.
What Are the Growth Opportunities for GNFT?
- Growth opportunity 1: The global NASH market is projected to grow at a CAGR of over 30% through 2028, driven by rising obesity rates and increased awareness of liver health. Genfit's NIS4 technology for diagnosing NASH could capture significant market share as healthcare providers seek effective diagnostic solutions.
- Growth opportunity 2: Elafibranor's Phase 3 trial outcomes could lead to market approval, opening new revenue streams. The primary biliary cholangitis market is expected to grow substantially, providing Genfit with a competitive advantage if Elafibranor is successfully commercialized.
- Growth opportunity 3: The collaboration with Labcorp for the commercialization of NASHnext positions Genfit to leverage Labcorp's extensive distribution network, enhancing market access and accelerating revenue generation from diagnostic solutions.
- Growth opportunity 4: The development of GNS561 for cholangiocarcinoma is timely as the incidence of this cancer type is rising. With limited treatment options available, successful clinical trials could position Genfit as a leader in this niche market.
- Growth opportunity 5: The increasing focus on personalized medicine provides Genfit with opportunities to tailor its diagnostic solutions and treatments, enhancing patient outcomes and potentially leading to higher market adoption rates.
What Opportunities Does GNFT Have?
- Expanding global market for NASH and liver disease treatments.
- Potential for successful commercialization of Elafibranor and GNS561.
- Growing demand for diagnostic solutions in liver health assessment.
What Threats Does GNFT Face?
- Intense competition from established and emerging biotechnology firms.
- Regulatory challenges in drug approval processes.
- Market volatility affecting investment and funding opportunities.
What Are GNFT's Competitive Advantages?
- Strong pipeline of innovative drug candidates with potential for market differentiation.
- Established partnerships with leading healthcare organizations enhance credibility and market reach.
- Focus on niche therapeutic areas with high unmet medical needs provides a competitive edge.
- Proprietary diagnostic technologies like NIS4 position Genfit as a leader in liver disease diagnostics.
- Experienced management team with a track record in biotechnology and pharmaceuticals.
What Does GNFT Do?
Founded in 1999 and headquartered in Loos, France, Genfit S.A. is a biopharmaceutical company dedicated to discovering and developing drug candidates and diagnostic solutions targeting metabolic and liver-related diseases. The company has made significant strides in the biotechnology sector, particularly with its lead product, Elafibranor, which is currently in Phase 3 clinical trials aimed at treating primary biliary cholangitis, a chronic liver disease. In addition to Elafibranor, Genfit is advancing its NIS4 technology, a diagnostic tool for nonalcoholic steatohepatitis (NASH) and liver fibrosis, which represents a critical area of unmet medical need. The company is also developing GNS561, an investigational treatment for cholangiocarcinoma (CCA), currently in Phase 1b/2 trials, and Nitazoxanide, which is in Phase 1 trials for acute-on-chronic liver failure. Genfit has established licensing agreements with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test, and with Genoscience Pharma for the development of GNS561. These strategic partnerships enhance Genfit's market position and broaden its reach in the healthcare landscape. With a dedicated workforce of 180 employees, Genfit continues to focus on innovation and research to address the growing challenges associated with liver diseases and metabolic disorders.
What Products and Services Does GNFT Offer?
- Develops innovative drug candidates for metabolic and liver diseases.
- Conducts clinical trials to evaluate the safety and efficacy of its products.
- Offers diagnostic solutions like NIS4 for liver disease assessment.
- Engages in strategic partnerships to enhance product development and market access.
- Focuses on addressing unmet medical needs in the healthcare sector.
- Operates primarily in the biotechnology industry with a strong emphasis on research and development.
How Does GNFT Make Money?
- Generates revenue through the commercialization of drug candidates upon successful clinical trial outcomes.
- Licenses diagnostic technologies to healthcare providers and laboratories.
- Collaborates with other pharmaceutical companies to co-develop and market treatments.
- Invests heavily in R&D to innovate and expand its product pipeline.
- Utilizes partnerships to leverage existing market channels for faster product access.
What Industry Does GNFT Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in drug development and increasing investment in healthcare innovation. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, with significant contributions from companies focusing on metabolic and liver diseases. Genfit S.A. operates within this dynamic landscape, where competition is fierce, particularly in the areas of NASH and liver disease treatments. As the demand for effective therapies continues to rise, Genfit's focus on innovative solutions positions it favorably among its peers.
Who Are GNFT's Key Customers?
- Healthcare providers seeking innovative treatments for liver diseases.
- Patients diagnosed with metabolic and liver-related conditions.
- Laboratories and diagnostic centers utilizing Genfit's diagnostic solutions.
- Pharmaceutical companies interested in collaboration for drug development.
- Investors looking for opportunities in the biotechnology sector.
How GNFT Is Valued
GNFT carries a market capitalization of $445.68M, placing it in the small-cap category. Relative to its peer group, GNFT's quantitative score of 69/100 is below the peer average of 92/100.
Company Profile
GNFT operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Loos, FR. The company is led by CEO M. Pascal Prigent. GNFT has traded publicly since 2019.
Key Financial Metrics
Return on assets is -54.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
GNFT's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.05 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project GNFT revenue of about $47.4M for fiscal 2026, with EPS near $-0.40. The estimate reflects 4 contributing analysts.
GNFT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- GNFT insiders seem to be holding steady, not selling off shares, which can signal confidence from those who know the company best.
- The buzz around GNFT in social trading circles is generally positive, with many seeing long-term potential.
- GNFT is getting some positive attention for its moves in the market, suggesting a growing recognition of its value.
- There's a feeling that GNFT is undervalued right now, with the potential for significant growth as it gains more traction.
Bear Case
- Some community members are worried about GNFT's ability to scale effectively and meet growing demand.
- There's a sense that GNFT might be overhyped, and the reality might not live up to the expectations.
- Recent market developments could create headwinds for GNFT, making it harder for them to gain market share.
- A few influential voices in the trading community are expressing doubts about GNFT's long-term prospects, raising concerns about its sustainability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GNFT Latest News
-
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
globenewswire.com · Jun 15, 2026
-
GENFIT : Résultats de l’Assemblée Générale Mixte du 15 juin 2026
globenewswire.com · Jun 15, 2026
-
GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp's OnDemand Offering for Identification of At-Risk MASH
globenewswire.com · Jun 8, 2026
-
GENFIT Annual General Meeting of June 15, 2026 - Shareholders' letter
globenewswire.com · Jun 2, 2026
GNFT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNFT.
Price Targets
Wall Street price target analysis for GNFT.
GNFT MoonshotScore
What does this score mean?
The MoonshotScore rates GNFT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
GENFIT : Résultats de l’Assemblée Générale Mixte du 15 juin 2026
GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp's OnDemand Offering for Identification of At-Risk MASH
GENFIT Annual General Meeting of June 15, 2026 - Shareholders' letter
Leadership: M. Pascal Prigent
CEO
M. Pascal Prigent has extensive experience in the biotechnology sector, having held various leadership roles in pharmaceutical companies. He holds a strong educational background in life sciences and has been instrumental in guiding Genfit's strategic direction since taking the helm.
Track Record: Under M. Pascal Prigent's leadership, Genfit has advanced its clinical pipeline and established key partnerships that enhance its market position. His focus on innovation and strategic growth has been pivotal in navigating the challenges of the biotechnology landscape.
GNFT ADR Information Sponsored
An American Depositary Receipt (ADR) is a negotiable certificate that represents shares in a foreign company, allowing U.S. investors to trade shares of foreign companies on U.S. exchanges. Genfit S.A. operates as a Level II ADR, providing investors with a way to invest in the company while benefiting from the convenience of U.S. market trading.
- Home Market Ticker: Euronext Paris, France
- ADR Level: 2
- ADR Ratio: 1:1
What Investors Ask About GNFT (GNFT) — Healthcare
What does Genfit S.A. do?
Genfit S.A. is a biopharmaceutical company that develops drug candidates and diagnostic solutions for metabolic and liver diseases. Its key products include Elafibranor, currently in Phase 3 trials for primary biliary cholangitis, and NIS4 technology for diagnosing nonalcoholic steatohepatitis (NASH). The company also works on GNS561 for cholangiocarcinoma and Nitazoxanide for acute-on-chronic liver failure.
What do analysts say about GNFT stock?
Analysts have a cautious outlook on GNFT stock, emphasizing the importance of successful clinical trial results for Elafibranor and GNS561. Key valuation metrics include the company's market cap of $445.68M and a focus on innovative solutions in the liver disease space. Analysts suggest that the success of ongoing trials will be critical for future growth.
What are the main risks for GNFT?
Genfit S.A. faces several risks, including the potential for clinical trial failures, which could significantly delay product commercialization. Regulatory hurdles may also pose challenges during the approval process for new drugs. Additionally, competition from larger firms in the biotechnology sector could impact Genfit's market share and growth potential.
What are the key factors to evaluate for GNFT?
GNFT holds an AI score of 69/100 (moderate). Not financial advice.
How frequently does GNFT data refresh on this page?
GNFT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GNFT's recent stock price performance?
GNFT moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline targeting significant unmet medical needs in liver diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNFT overvalued or undervalued right now?
Valuing GNFT requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GNFT?
Before investing in GNFT, research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information and may be subject to change.